-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Molecular Partners, TG Therapeutics, 17EdTech, and Enochian and Encourages Investors to Contact the Fir
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Missfresh, Molecular Partners, TG Therapeutics, and 17EdTech and Encourages Investors to Contact the Fi
-
-
-
-
-
-
-
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
-
-
-
-
-
-
-
TG Therapeutics (TGTX) Announces FDA Set ADCOM Meeting for April 22, 2022
-
-
-
-
-
-
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple
-
-
-
-
-
-
-
TG Therapeutics (TGTX) Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia
-
-
-
-
-
-
-
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting
-
15,767 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

